Paper41268321
Pharmacokinetics and pharmacological activities of protopanaxatriol.
Hu Y and 2 others. J Ginseng Res, 2025. Cited by 6 papers, by iCite.
Cite this record
ConductScience Library. Pharmacokinetics and pharmacological activities of protopanaxatriol. Papers, record 41268321. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41268321
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References90
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 40843020 | Protopanaxatriol, a ginsenoside metabolite, induces apoptosis in colorectal cancer cells and arrests their cell cycle by targeting AKT. | J Ginseng Res | 2025 | https://conductscience.org/library/papers/40843020 | PubMed |
| 2 | 36644389 | Roles of ginsenosides in sepsis. | J Ginseng Res | 2023 | https://conductscience.org/library/papers/36644389 | PubMed |
| 3 | 36382689 | Contribution of Chinese herbal medicine in the treatment of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis of randomized controlled trials. | Phytother Res | 2023 | https://conductscience.org/library/papers/36382689 | PubMed |
| 4 | 27818927 | Simultaneous quantification of ginsenoside Rg1 and its metabolites by HPLC-MS/MS: Rg1 excretion in rat bile, urine and feces. | Acta Pharm Sin B | 2016 | https://conductscience.org/library/papers/27818927 | PubMed |
| 5 | 34749235 | Ginsenoside (20S)-protopanaxatriol induces non-protective autophagy and apoptosis by inhibiting Akt/mTOR signaling pathway in triple-negative breast cancer cells. | Biochem Biophys Res Commun | 2021 | https://conductscience.org/library/papers/34749235 | PubMed |
| 6 | 22563256 | Effects of protopanaxatriol-ginsenoside metabolites on rat N-methyl-d-aspartic Acid receptor-mediated ion currents. | Korean J Physiol Pharmacol | 2012 | https://conductscience.org/library/papers/22563256 | PubMed |
| 7 | 23391424 | Different pharmacokinetics of the two structurally similar dammarane sapogenins, protopanaxatriol and protopanaxadiol, in rats. | Fitoterapia | 2013 | https://conductscience.org/library/papers/23391424 | PubMed |
| 8 | 15036657 | 20(S)-Protopanaxatriol, one of ginsenoside metabolites, inhibits inducible nitric oxide synthase and cyclooxygenase-2 expressions through inactivation of nuclear factor-kappaB in RAW 264.7 macrophages stimulated with lipopolysaccharide. | Cancer Lett | 2004 | https://conductscience.org/library/papers/15036657 | PubMed |
| 9 | 39036733 | Effects of Panax species and their bioactive components on allergic airway diseases. | J Ginseng Res | 2024 | https://conductscience.org/library/papers/39036733 | PubMed |
| 10 | 34271119 | Inhibitory activities of 20(R, S)-protopanaxatriol against epidermal growth factor receptor tyrosine kinase. | Food Chem Toxicol | 2021 | https://conductscience.org/library/papers/34271119 | PubMed |
| 11 | 34975775 | Solid-State Fermentation With Aspergillus cristatus Enhances the Protopanaxadiol- and Protopanaxatriol-Associated Skin Anti-aging Activity of Panax notoginseng. | Front Microbiol | 2021 | https://conductscience.org/library/papers/34975775 | PubMed |
| 12 | 26109499 | 20(S)-protopanaxatriol inhibits liver X receptor α-mediated expression of lipogenic genes in hepatocytes. | J Pharmacol Sci | 2015 | https://conductscience.org/library/papers/26109499 | PubMed |
| 13 | 40118196 | Traditional Herbal Medicine Pithecellobium clypearia (Jack) Benth: Research progress in chemical constituents and pharmacological activities. | J Ethnopharmacol | 2025 | https://conductscience.org/library/papers/40118196 | PubMed |
| 14 | 36292949 | Integrated Metabolomics and Network Pharmacology to Decipher the Latent Mechanisms of Protopanaxatriol against Acetic Acid-Induced Gastric Ulcer. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36292949 | PubMed |
| 15 | 31926987 | Ginsenoside metabolite 20(S)-protopanaxatriol from Panax ginseng attenuates inflammation-mediated NLRP3 inflammasome activation. | J Ethnopharmacol | 2020 | https://conductscience.org/library/papers/31926987 | PubMed |
| 16 | 38465212 | Sustainable production of natural products using synthetic biology: Ginsenosides. | J Ginseng Res | 2024 | https://conductscience.org/library/papers/38465212 | PubMed |
| 17 | 37037488 | 20(S)-protopanaxatriol inhibited D-galactose-induced brain aging in mice via promoting mitochondrial autophagy flow. | Phytother Res | 2023 | https://conductscience.org/library/papers/37037488 | PubMed |
| 18 | 38195040 | Rare ginsenosides: A unique perspective of ginseng research. | J Adv Res | 2024 | https://conductscience.org/library/papers/38195040 | PubMed |
| 19 | 36644384 | Microbiota, co-metabolites, and network pharmacology reveal the alteration of the ginsenoside fraction on inflammatory bowel disease. | J Ginseng Res | 2023 | https://conductscience.org/library/papers/36644384 | PubMed |
| 20 | 30269219 | Protective effects of protopanaxatriol on acute liver injury induced by concanavalin A. | Naunyn Schmiedebergs Arch Pharmacol | 2019 | https://conductscience.org/library/papers/30269219 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42719414 | Emerging and underexplored ginsenosides in cancer therapy (2020-2025): Beyond cytotoxic mechanisms. | J Ginseng Res | 2026 | https://conductscience.org/library/papers/42719414 | PubMed |
| 42719322 | The roles of ginseng and ginsenosides for immune regulation: Relation to immunometabolic responses. | J Ginseng Res | 2026 | https://conductscience.org/library/papers/42719322 | PubMed |
| 42395029 | Panax ginseng as a proteome-metabolome medicinal ecosystem: Reframing pharmacology beyond a strictly saponin-centric paradigm. | J Ginseng Res | 2026 | https://conductscience.org/library/papers/42395029 | PubMed |
| 42395025 | Ginsenosides from Panax ginseng: Their mechanisms, microbiome determinants, and translational strategies in therapeutic activity against cancer. | J Ginseng Res | 2026 | https://conductscience.org/library/papers/42395025 | PubMed |
| 42395013 | Ginsenoside Rb2 modulates the skin barrier by targeting Src to regulate PI3K/Akt signaling in HaCaT cells. | J Ginseng Res | 2026 | https://conductscience.org/library/papers/42395013 | PubMed |
| 41788581 | Cellular and molecular regulation of skin by ginseng and its bioactive Constituents: A review of studies from 2021 to 2025. | J Ginseng Res | 2026 | https://conductscience.org/library/papers/41788581 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41268321
GET https://conductscience.org/api/papers/v1/41268321/references?page=2